Effect of CPAP in the Worsening of Renal Function in Early Stages of Chronic Kidney Disease (CKD) (Renas)

Objectives: Evaluate the effect of CPAP to reduce the progression of chronic kidney disease or CKD (the decline of glomerular filtration rate is ≥ 30%) in patients with early-stage renal disease and sleep apnea syndrome (OSAS). Other objectives are; determine the prevalence of OSAS in patients with early-stage renal disease and evaluate the changes in inflamatories markers and endothelial damage, the state of KDIGO, cardiovascular events, mortality and cost-effectiveness analysis in CPAP group versus non-CPAP group patients.

Methods: A prospective, multicentric, randomized and controlled study will be carried out for 3 years. Early-stage renal disease (G1-3 KDIGO) and OSAS patients will be included. The investigators will make a respiratory polygraphy to determinate OSAS (AHI ≥15/h) and after that, the investigators randomized patients in 2 groups; CPAP group and control group (non-CPAP treatment). Patients with AHI <15/h (non-OSAS) will be the reference group and the half of these patients, randomly chosen, will be followed up at the end of the follow up.

Statistic analysis: the investigators will analyze the differences in glomerular filtration rate before and after the treatment, comparing the percentage of patients with CKD progression for both groups. The investigators will use the chi square test with raw data and adjusted for confounding variables using intention to treat analysis with imputation of missing values.

Study Overview

• Status: Unknown
• Conditions: Sleep Apnea; Chronic Kidney Insufficiency
• Intervention / Treatment: Device: CPAP; Other: conservative treatment

Detailed Description

There is a bidirectional involvement between the chronic kidney disease (CKD) and sleep apnea syndrome (OSAS). The declining of renal function, the fluid overloading and the disturbance of ventilation control could cause sleep apneas. On the other hand, the nocturnal hypoxia in patients with OSAS has been associated with changes in the renin-angiotensin system and sympathetic nervous system and production of reactive oxygen species. These findings are relationed with the deterioration of kidney function.

• Study Type: Interventional
• Enrollment (Anticipated): 700
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Cáceres, Spain, 10003
    • Recruiting
    • Jaime Corral
    • Contact: Jaime Corral, MD; Phone Number: 927256204; Email: jcorral@separ.es

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients referred to the outpatient nephrology department with a diagnosis of chronic kidney disease stages G1-3 KDIGO
• Older than18 years
• Habitual snoring or observed apneas
• Scale sleep sleepiness (Epworth Test) with 11 points or lower.

Exclusion Criteria:

• Very debilitating chronic or neoplastic disease
• Respiratory failure (PaO 2 <55 mm Hg).
• Other symptoms of suspected sleep disorder different from OSAS.
• Patients unable to perform self-administered questionnaires.
• Patients with> 50% of central apnea or Cheyne-Stokes.
• Patients who do not sign the informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: cpap group; CPAP treatment plus conservative treatment with lifestyle modifications.	Device: CPAP; continuous positive pressure in the airway
ACTIVE_COMPARATOR: control group; Conservative treatment with lifestyle modifications.	Other: conservative treatment; conservative treatment group with lifestyle modifications

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To test whether treatment with CPAP in patients with moderate to severe OSAS and CKD in stages KDIGO G1-3, reduces the progression of renal disease (30% drop in GF) after 2 years of followed up.	Number of participants with chronic kidney disease (CKD) and obstructive sleep apnea syndrome (OSAS) with a 30% decline in estimated glomerular filtration rate (eGFR) using the CKD-EPI (CKD Epidemiology Collaboration) 2009 creatinine equation after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To estimate the prevalence of OSAS in patients with CKD stages G1-3 KDIGO	Number of participants with CKD and snoring and observed apneas with an apnea and hypoapnea index (AHI) ≥15/hour in home-based polysomnography.	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
To test whether treatment with CPAP reduces the albumin / creatinine ratio in urine.	Number of participants with CKD and OSAS with a decline in urine albumin to creatinine ratio.	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
To evaluate whether treatment with CPAP reduces serum Cystatin C	Number of participants with CKD and OSAS with a decline in serum cystatin C levels	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
To evaluate whether treatment with CPAP reduces inflammation-endothelial disfunction markers	Number of participants with CKD and OSAS with a decline in inflammation-endothelial disfunction markers (interleukine-6, interleukine-8, reactive C protein, sedimentation rate, asymmetric dimethylaginine or ADMA, intercellular adhesion molecule 1 or ICAM-1, vascular adhesion protein 1 or VCAM 1, vascular endothelial growth factor or VEGF)	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
Evaluate whether treatment with CPAP reduces the progression of CKD to a different stage	number of participants with CKD and OSAS with a change to a higher CKD stage according to eGFR.	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
to test wheather CPAP reduces the percentage of patients achieving replacement therapy	number of participants with CKD and OSAS who need renal replacement therapy (haemodialysis, peritoneal dialysis or renal transplantation)	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
Evaluate wheather treatment with CPAP reduces the incidence of cardiovascular events	number of participants with CKD and OSAS who suffered a cardiovascular event (myocardial infarction, stroke, hospitalization for heart failure, atrial fibrillation)	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
Evaluate wheather treatment with CPAP reduces the mortality	number of participants with CKD and OSAS with CPAP treatment who died (all-cause mortality)	after 2 years of followed up (each patient will be followed up for at least 2 years - range from 2 to 3 years)
Evaluation of the cost-effectiveness of treatment groups with and without CPAP	Cost-effectiveness of treatment groups conducting a cost-effectiveness study that allow us to estimate the incremental cost-effectiveness ratio (ICER) of CPAP treatment group compared to the conventional treatment group	after 2 years of followed up (each patient will be followed up for at least 2 years-range from 2 to 3 years)
Compare the evolution of inflammation-endothelial disfunction markers in NO-OSAS group versus OSAS group	Number of participants with NO-OSAS versus OSAS who have a decline in inflammation-endothelial disfunction markers (interleukine-6, interleukine-8, reactive C protein, sedimentation rate, asymmetric dimethylaginine or ADMA, intercellular adhesion molecule 1 or ICAM-1, vascular adhesion protein 1 or VCAM 1, vascular endothelial growth factor or VEGF)	after 2 years of followed up (each patient will be followed up for at least 2 years-range from 2 to 3 years)
Compare the worsening of the glomerular filtration in NO OSAS group versus OSAS group	number of participants with NO OSAS versus OSAS who have a worsening of the glomerular filtration.	after 2 years of followed up (each patient will be followed up for at least 2 years-range from 2 to 3 years)
Compare the percentage of patients achieving renal replacement therapy in NO OSAS group versus OSAS group	number of participants who need renal replacement therapy in NO OSAS group versus OSAS group	after 2 years of followed up (each patient will be followed up for at least 2 years-range from 2 to 3 years)

Collaborators and Investigators

• Sponsor: Sociedad Española de Neumología y Cirugía Torácica

Publications and helpful links

General Publications

• Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31. Erratum In: Lancet. 2013 Jul 20;382(9888):208.
• James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010 Apr 10;375(9722):1296-309. doi: 10.1016/S0140-6736(09)62004-3. Erratum In: Lancet. 2010 Jul 17;376(9736):162.
• Otero A, de Francisco A, Gayoso P, Garcia F; EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78-86. doi: 10.3265/Nefrologia.pre2009.Dic.5732. Epub 2009 Dec 14.
• Lloberes P, Duran-Cantolla J, Martinez-Garcia MA, Marin JM, Ferrer A, Corral J, Masa JF, Parra O, Alonso-Alvarez ML, Teran-Santos J. Diagnosis and treatment of sleep apnea-hypopnea syndrome. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol. 2011 Mar;47(3):143-56. doi: 10.1016/j.arbres.2011.01.001. No abstract available. Erratum In: Arch Bronconeumol. 2011 Jul;47(7):378. English, Spanish.
• Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. doi: 10.1056/NEJM199304293281704.
• Nicholl DDM, Ahmed SB, Loewen AHS, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC, Hanly PJ. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012 Jun;141(6):1422-1430. doi: 10.1378/chest.11-1809. Epub 2012 Jan 5.
• Perl J, Unruh ML, Chan CT. Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis'? Kidney Int. 2006 Nov;70(10):1687-93. doi: 10.1038/sj.ki.5001791. Epub 2006 Sep 13.
• Hanly PJ, Ahmed SB. Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease? Chest. 2014 Oct;146(4):1114-1122. doi: 10.1378/chest.14-0596.
• Beecroft J, Duffin J, Pierratos A, Chan CT, McFarlane P, Hanly PJ. Enhanced chemo-responsiveness in patients with sleep apnoea and end-stage renal disease. Eur Respir J. 2006 Jul;28(1):151-8. doi: 10.1183/09031936.06.00075405. Epub 2006 Mar 1.
• Faulx MD, Storfer-Isser A, Kirchner HL, Jenny NS, Tracy RP, Redline S. Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep. 2007 Jul;30(7):923-9. doi: 10.1093/sleep/30.7.923.
• Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol. 2002 Mar;13(3):729-733. doi: 10.1681/ASN.V133729.
• Nicholl DD, Hanly PJ, Poulin MJ, Handley GB, Hemmelgarn BR, Sola DY, Ahmed SB. Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med. 2014 Sep 1;190(5):572-80. doi: 10.1164/rccm.201403-0526OC.
• Kuzniar TJ, Klinger M. Sleep apnea, continuous positive airway pressure, and renal health. Am J Respir Crit Care Med. 2014 Sep 1;190(5):486-7. doi: 10.1164/rccm.201407-1359ED. No abstract available.
• Ahmed SB, Ronksley PE, Hemmelgarn BR, Tsai WH, Manns BJ, Tonelli M, Klarenbach SW, Chin R, Clement FM, Hanly PJ. Nocturnal hypoxia and loss of kidney function. PLoS One. 2011 Apr 29;6(4):e19029. doi: 10.1371/journal.pone.0019029.
• Sakaguchi Y, Hatta T, Hayashi T, Shoji T, Suzuki A, Tomida K, Okada N, Rakugi H, Isaka Y, Tsubakihara Y. Association of nocturnal hypoxemia with progression of CKD. Clin J Am Soc Nephrol. 2013 Sep;8(9):1502-7. doi: 10.2215/CJN.11931112. Epub 2013 Jun 6.
• Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, Tracy RP, Rueschman M, Blumenthal RS, Lewis EF, Bhatt DL, Redline S. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014 Jun 12;370(24):2276-85. doi: 10.1056/NEJMoa1306766.
• Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med. 2004 Feb 1;169(3):361-6. doi: 10.1164/rccm.200306-752OC. Epub 2003 Nov 3.
• Koga S, Ikeda S, Yasunaga T, Nakata T, Maemura K. Effects of nasal continuous positive airway pressure on the glomerular filtration rate in patients with obstructive sleep apnea syndrome. Intern Med. 2013;52(3):345-9. doi: 10.2169/internalmedicine.52.8468. Epub 2013 Feb 1.
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. Erratum In: Ann Intern Med. 2011 Sep 20;155(6):408.
• Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014 Dec;64(6):821-35. doi: 10.1053/j.ajkd.2014.07.030. Epub 2014 Oct 16.
• Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014 Dec;64(6):848-59. doi: 10.1053/j.ajkd.2014.08.017. Epub 2014 Oct 16.
• Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodward M, Coresh J, Levey AS. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis. 2014 Dec;64(6):867-79. doi: 10.1053/j.ajkd.2014.08.019. Epub 2014 Oct 31.
• Vigil A, Condes E, Vigil L, Gallar P, Oliet A, Ortega O, Rodriguez I, Ortiz M, Herrero JC, Mon C, Cobo G, Jimenez J. Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease. Int J Nephrol. 2014;2014:127943. doi: 10.1155/2014/127943. Epub 2014 Feb 11.

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 20, 2017
• Primary Completion (ANTICIPATED): November 20, 2019
• Study Completion (ANTICIPATED): May 20, 2020

Study Registration Dates

• First Submitted: September 23, 2016
• First Submitted That Met QC Criteria: October 19, 2017
• First Posted (ACTUAL): October 24, 2017

Study Record Updates

• Last Update Posted (ACTUAL): March 6, 2018
• Last Update Submitted That Met QC Criteria: March 5, 2018
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: CPAP, Chronic kidney disease, sleep apnea
• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Apnea; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Urologic Diseases; Sleep Apnea Syndromes; Kidney Diseases; Renal Insufficiency, Chronic; Renal Insufficiency
• Other Study ID Numbers: PI15/00137

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No